Frazier Life Sciences Management, L.P.: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1892134) · Explore on the interactive board
Frazier Life Sciences Management, L.P. disclosed 41 US equity positions worth $4.6bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is MIRM at 19.6% of the reported book, followed by NEWAMSTERDAM PHARMA COMPANY, ERAS. The top ten holdings are 73.6% of the book, and the portfolio behaves like about 12 equal-weight positions. Versus the prior filing it opened 6 new positions, added to 8, reduced 1 and exited 3. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Frazier Life Sciences Management, L.P. own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 6 new, 8 added, 1 reduced, 3 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 19.6% | $899.1m | 7,679,684 | 0% | held |
| 2 | NEWAMSTERDAM PHARMA COMPANY | 13.3% | $613.0m | 18,088,902 | 7% | added | |
| 3 | ERAS ERASCA INC | Healthcare | 10.0% | $457.5m | 24,975,188 | 1% | added |
| 4 | MBX MBX BIOSCIENCES INC | Healthcare | 8.0% | $367.2m | 6,652,013 | 0% | held |
| 5 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 5.6% | $258.9m | 9,874,511 | 0% | held |
| 6 | TRVI TREVI THERAPEUTICS INC | Healthcare | 4.0% | $185.4m | 9,939,447 | -0% | held |
| 7 | KRYS KRYSTAL BIOTECH INC | Healthcare | 3.9% | $178.9m | 481,307 | 0% | held |
| 8 | MAZE MAZE THERAPEUTICS INC | Healthcare | 3.3% | $150.2m | 5,032,915 | 10% | added |
| 9 | PHAT PHATHOM PHARMACEUTICALS INC | Healthcare | 2.9% | $135.3m | 12,466,489 | 0% | held |
| 10 | PVLA PALVELLA THERAPEUTICS INC NE | Healthcare | 2.9% | $134.8m | 882,400 | 0% | held |
| 11 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 2.5% | $115.3m | 1,548,139 | -55% | reduced |
| 12 | IRON DISC MEDICINE INC | Healthcare | 2.2% | $99.1m | 1,354,852 | 0% | held |
| 13 | CYTK CYTOKINETICS INC | Healthcare | 2.2% | $98.8m | 1,159,879 | 0% | held |
| 14 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.5% | $70.0m | 3,153,082 | 0% | held |
| 15 | ASND ASCENDIS PHARMA A/S | Healthcare | 1.3% | $60.1m | 225,155 | 69% | added |
| 16 | SVRA SAVARA INC | Healthcare | 1.3% | $59.9m | 9,720,852 | 0% | held |
| 17 | PARABILIS MEDICINES INC | 1.1% | $52.6m | 1,920,805 | – | new | |
| 18 | AURA AURA BIOSCIENCES INC | 1.1% | $50.4m | 7,100,000 | 39% | added | |
| 19 | ACHV ACHIEVE LIFE SCIENCE INC | 1.1% | $49.7m | 7,614,836 | – | new | |
| 20 | VOR VOR BIOPHARMA INC | Healthcare | 1.0% | $46.8m | 2,543,939 | 0% | held |
| 21 | ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 1.0% | $46.7m | 22,446,668 | 491% | added |
| 22 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 1.0% | $45.9m | 728,644 | 0% | held |
| 23 | BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 0.9% | $40.1m | 4,009,240 | 0% | held |
| 24 | ALKS ALKERMES PLC | Healthcare | 0.8% | $36.7m | 700,647 | 0% | held |
| 25 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 0.8% | $36.4m | 1,438,198 | 0% | held |
| 26 | ZLAB ZAI LAB LTD | Healthcare | 0.8% | $36.1m | 1,902,320 | 0% | held |
| 27 | MNKD MANNKIND CORP | Healthcare | 0.6% | $28.1m | 6,600,000 | 12% | added |
| 28 | DSGN DESIGN THERAPEUTICS INC | Healthcare | 0.6% | $26.2m | 1,809,854 | – | new |
| 29 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 0.6% | $26.1m | 4,925,374 | 0% | held |
| 30 | STTK SHATTUCK LABS INC | Healthcare | 0.6% | $26.0m | 3,750,000 | – | new |
| 31 | KAILERA THERAPEUTICS INC | 0.5% | $24.2m | 1,100,000 | – | new | |
| 32 | GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 0.5% | $24.2m | 1,000,000 | 0% | held |
| 33 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 0.5% | $22.5m | 4,824,725 | 9% | added |
| 34 | RLAY RELAY THERAPEUTICS INC | Healthcare | 0.4% | $19.0m | 1,015,693 | – | new |
| 35 | EOLS EVOLUS INC | Healthcare | 0.4% | $18.3m | 2,630,665 | 0% | held |
| 36 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 0.3% | $15.4m | 484,782 | 0% | held |
| 37 | VALNEVA SE | 0.3% | $12.0m | 2,291,666 | 0% | held | |
| 38 | NEWAMSTERDAM PHARMA COMPANY | 0.2% | $10.7m | 500,333 | 0% | held | |
| 39 | AUTL AUTOLUS THERAPEUTICS LTD | Healthcare | 0.2% | $7.1m | 4,447,910 | 0% | held |
| 40 | XLO XILIO THERAPEUTICS INC | 0.1% | $4.0m | 422,505 | 0% | held | |
| 41 | IBIO IBIO INC | 0.1% | $3.4m | 1,953,467 | 0% | held |
What did Frazier Life Sciences Management, L.P. sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| 4XC1 KALVISTA PHARMACEUTICALS INC | 48.0% | $99.9m |
| RVMD REVOLUTION MEDICINES INC | 31.6% | $65.7m |
| AGIO AGIOS PHARMACEUTICALS INC | 20.4% | $42.5m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 82.1% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Frazier Life Sciences Management, L.P.'s portfolio?
Across every quarter Frazier Life Sciences Management, L.P. has filed, its median largest position is 18.9% of the book and its median top-ten weight is 73.5%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 3.0 completed holding spells, the median lasted 1.0 quarters; 41.0 positions are still open and their final length is unknown.